Skip to main content

Table 3 Effects of MR antagonists in peritoneal dialysis patients

From: Mineralocorticoid receptor antagonists in dialysis patients

Author Number of patients Administration period Study duration Results Change of plasma potassium
Hausmann et al. [57] One PD patient Spironolactone 25 mg/day 10 months LVEF increased. Potassium level was below 5.1 at pretreatment and below 5.5 mEq/l after spironolactone treatment.
Taheri et al. [58] 9 PD patients with heart failure Spironolactone 25 mg every other day 6 months LVEF increased. There was no significantly difference between spironolactone and placebo groups (P > 0.05). One patient in the spironolactone group developed hyperkalemia (K = 5.70 mEq/l).
Ito et al. [60] 78 PD patients Spironolactone 25 mg/day 2 years LV mass index and LVEF improved. Potassium levels were significantly higher in the spironolactone group after 6 and 12 months (P < 0.05).
Two patients in the spironolactone group developed hyperkalemia (K = 6.0 mEq/l), and one patient (K = 6.1 mEq/l) in the control group.
Yongsiri et al. [59] 24 PD patients with hypokalemia Spironolactone 25 mg/day 4 weeks   Potassium levels 4.23 ± 0.64 at base line and 3.90 ± 0.59 mEq/l after 4 weeks (P = 0.077). One patient in the spironolactone group developed hyperkalemia (K = 5.6 mEq/l).
Yelken et al. [72] 23 PD patients Spironolactone 25 mg/day 6 months Dialysate CA125 increased.
Residual GFR declined.
Potassium level 4.3 ± 0.5 at baseline and 4.4 ± 0.6 mEq/l after 6 months (P = 0.488).
Vazquez-Rangel et al. [73] 9 PD patients Spironolactone 25 mg/day 6 months CD20 and collagen IV levels in peritoneal biopsy specimens decreased. Potassium levels 4.8 ± 0.4 in the spironolactone group and 4.4 ± 0.5 mEq/l in the control group (P = 0.2).
  1. CA125 cancer antigen 125, EF ejection fraction, GFR glomerular filtration rate, LV left ventricular, MR mineralocorticoid receptor, PD peritoneal dialysis